hepatitis B

TAF Is Superior to TDF in Reducing Bone, Renal Risks

Switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) is safe and effective for patients with chronic hepatitis B and TDF risk factors, according to new findings.

These findings were presented this week at Digestive Disease Week 2018 in Washington, DC.

IF YOU LIKE THIS, READ MORE...

PPIs Along Can Not Reduce GERD Burden

More Digestive Disease Week 2018 coverage

Because patients responded well to TAF therapy in 48- and 96-week trials and because TAF was superior to TDF in reducing renal and bone risk factors, the researchers are conducting an ongoing, Phase 3 study to better understand the 1-year safety profile and efficacy of switching patients to TAF therapy.

For their study, the researchers randomly assigned 1298 patients who were positive and negative for the HBeAG antigen to receive either TAF 25 mg daily or TDF 300 mg daily for 96 weeks. Then 540 patients were switched to an open label TAF 25 mg daily.

A sub-analysis examined older patients with bone, renal, and other risk factors associated with TDF use.

Results showed that switching from TDF to TAF had:

  • Improved renal risk factors, with more patients experiencing an improvement in chronic kidney disease stage after 1 year.
  • Improved hip and spine bone mineral density after 1 year.
  • Maintained antiretroviral efficacy at week 144.
  • Improved alanine aminotransferase normalization at week 144.

“In a subset of patients with [risk factors] to [tenofovir disoproxil fumarate] use, switching from [tenofovir disoproxil fumarate] to [tenofovir alafenamide] showed improvements in renal and bone safety parameters and higher normalization of [alanine aminotransferase] while antiviral efficacy was maintained at one year,” the researchers concluded.

—Amanda Balbi

Reference:

Qian Pan C, Gane E, Seto WK, et al. 1 year safety and efficacy data in chronic HBV patients with risk factors for tenofovir disoproxil fumarate (TDF) after switching from TDF to tenofovir alafenamide (TAF). Paper presented at: Digestive Disease Week 2018; June 2-5, 2018; Washington, DC. https://ep70.eventpilot.us/web/page.php?page=IntHtml&project=DDW18&id=2920280. Accessed June 5, 2018.

 

Listen to our podcast with Dr Eiyu Matsumoto about HIV infection: